title: High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902.
abstract: Gemtuzumab ozogamicin (GO), an anti-CD33 immunoconjugate, was combined with high dose cytarabine (HiDAC; cytarabine 3g/m(2) over 3h daily for 5 days) for adults with relapsed or refractory AML. HiDAC plus GO 9mg/m(2) on day 7 and 4.5mg/m(2) on day 14 was not tolerated, but HiDAC followed by GO 9mg/m(2) on day 7 was safe: 12/37 (32%) patients with relapsed AML achieved complete remission. Median overall survival was 8.9 months. No grade 4 hepatic veno-occlusive disease was observed. This regimen merits further study, both in this setting and as a remission consolidation therapy.
authors.affiliation: Dana-Farber Cancer Institute, Boston, MA 02115, USA. rstone@partners.org
authors.forename: Richard M
authors.initials: RM
authors.lastname: Stone
authors.forename: Barry
authors.initials: B
authors.lastname: Moser
authors.forename: Ben
authors.initials: B
authors.lastname: Sanford
authors.forename: Philip
authors.initials: P
authors.lastname: Schulman
authors.forename: Jonathan E
authors.initials: JE
authors.lastname: Kolitz
authors.forename: Steven
authors.initials: S
authors.lastname: Allen
authors.forename: Wendy
authors.initials: W
authors.lastname: Stock
authors.forename: Ilene
authors.initials: I
authors.lastname: Galinsky
authors.forename: Ravi
authors.initials: R
authors.lastname: Vij
authors.forename: Guido
authors.initials: G
authors.lastname: Marcucci
authors.forename: David
authors.initials: D
authors.lastname: Hurd
authors.forename: Richard A
authors.initials: RA
authors.lastname: Larson
mesh_terms: D000368:Aged; D000617:Aminoglycosides / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016022:Case-Control Studies; D015331:Cohort Studies; D003561:Cytarabine / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D005260:Female; D000079982:Gemtuzumab; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000473:pathology; D012074:Remission Induction; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000617:Aminoglycosides; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D003561:Cytarabine; D000079982:Gemtuzumab; D015255:Idarubicin